Objective: The use of corticosteroids is frequent in critically-ill patients. However, little information is available on their effects in patients with intensive care unit-acquired pneumonia. We assessed patients' characteristics, microbial etiology, inflammatory response, and outcomes of previous corticosteroid use in patients with intensive care unit-acquired pneumonia.
V entilator-associated pneumonia (VAP) is a major cause of morbidity and mortality (1) (2) (3) , despite advances in antimicrobial therapy, supportive care, and the use of a broad range of preventive measures (1, (4) (5) (6) . Importantly, several cofactors are likely to play a role in the poor outcome of these patients, such as the severity of the illness, preexisting conditions, and the host response to infection (6) (7) (8) .
Corticosteroids are administered for a wide variety of indications to criticallyill patients (9) (10) (11) . A large retrospective study (12) reported that 26% patients from a mixed critically-ill population were treated with systemic corticosteroids; the use of these drugs is as much as 55% in patients ventilated for >7 days (13) and 69% in septic patients (14) . Interestingly, some of the most common indications for systemic corticosteroids, such as head trauma (8, 15, 16) and chronic obstructive lung disease (7, 15) , are strongly associated with VAP and intensive care unit (ICU)-acquired pneumonia.
Several studies (7, (17) (18) (19) (20) (21) have evaluated the use of systemic corticosteroids during stay in the ICU with controversial results regarding response to treatment and mortality. Although the role of corticosteroids in preventing VAP in multiple trauma patients has been recently reported (16) , no studies have comprehensively assessed the effects of systemic corticosteroids on the outcomes of patients with ICU-acquired pneumonia.
Thus, because previous systemic corticosteroid treatment may potentially affect the dynamics of the infection, complications, and outcomes of these patients, we assessed the characteristics, microbial etiology, systemic inflammatory response, and outcomes of corticosteroid treatment in a cohort of patients with ICU-acquired pneumonia.
METHODS
Study Population. The study was conducted in six medical and surgical ICUs, with a total of 45 beds, in an 800-bed university hospital. Data were collected prospectively from January 2007 to January 2011. The investigators made daily rounds in each ICU. Patients older than 18 yrs, admitted to these ICUs for 48 hrs or more, with clinical suspicion of ICU-acquired pneumonia were consecutively included in the study. Only the first occurrence of pneumonia was evaluated. Patients with severe immunosuppression (neutropenia after chemotherapy or hematopoietic transplant, drug-induced immunosuppression in solid-organ transplant or cytotoxic therapy, and patients infected with the human immunodeficiency virus) were excluded. The institution's internal review board approved the study, and written informed consent was obtained from the patients or their next-of-kin.
Definition of Pneumonia, Microbiologic Processing, and Antimicrobial Treatment. Clinical suspicion of pneumonia was based on either clinical criteria (new or progressive radiological pulmonary infiltrate together with at least two of the following clinical signs: temperature >38ºC or <36ºC; leukocytosis >12,000/mm 3 or leucopenia <4,000/mm 3 ; or purulent respiratory secretions) (1, 3, 22) or a simplified Clinical Pulmonary Infectious Score (CPIS) ≥6 (23) .
Microbiology evaluation, initial empiric antimicrobial treatment, and response to the treatment of this population were addressed in a previous study (3) . VAP was diagnosed in patients with previous invasive mechanical ventilation for 48 hrs or more, whereas nonventilator ICU-acquired pneumonia (NV-ICUAP) was defined as those cases that did not meet VAP criteria (3). Early-onset pneumonia was defined as occurring within the first 4 days of hospitalization (1) .
Analysis of Effects of Previous Systemic Corticosteroids. The outcomes of patients, who received an equivalent dosage of at least 20 mg/day of systemic methylprednisolone in the previous 2 days (including the day of diagnosis), prior to the development of ICUacquired pneumonia, were compared with the outcomes of patients who did not receive corticosteroid treatment. Patients who received steroid treatment at admission to hospital but were not receiving this treatment until 2 days before pneumonia diagnosis were included in the no treatment group. Long-term corticosteroid use was defined as chronic treatment with a prednisone equivalent dosage of >30 mg/day for >30 days, before admission to hospital (21) . We computed the cumulative dosage of corticosteroids received before the onset of pneumonia, expressed as methylprednisolone equivalent dosage. The indication and dosage of systemic corticosteroid treatment was decided by the attending physicians.
Assessment of Systemic Inflammatory Response. We evaluated the serum levels of interleukin-6, interleukin-8, tumor necrosis factor-α, C-reactive protein, and procalcitonin within the first 24 hrs and on the third day after the diagnosis of pneumonia. All methods of these analyses have been recently described in detail (24) . We also determined midregional proadrenomedullin (MR-proADM) using a test based on the time-resolved amplified cryptate emission technology (KRYPTOR; BRAHMS AG, Hennigsdorf, Germany). MR-proADM has a normal reference range of 0.33 ± 0.7 nmol/L.
Data Collection. All relevant data were collected at admission and at onset of pneumonia from the medical records and bedside charts. We also noted the indication for use of systemic corticosteroids and clinical, laboratory, radiologic, and microbiologic information. We calculated the Acute Physiology and Chronic Health Evaluation (APACHE)-II (25) and the Sequential Organ Failure Assessment (SOFA) (26) scores at admission to the ICU and on diagnosis of pneumonia. Patients were followed up to their death or up to 28 days after the diagnosis of pneumonia. Septic shock (27) and acute respiratory distress syndrome (ARDS) (28) were defined according to the previously described criteria.
Outcomes. The primary outcome was a comparison of 28-day survival after the diagnosis of ICU-acquired pneumonia (29) between patients with and without corticosteroid treatment. Secondary outcomes included microbiologic patterns, length of mechanical ventilation, ICU and hospital stay, the need for intubation for NV-ICUAP patients, ventilator-free days at 28 days (30), development of ICU-pneumonia-related septic shock, and nonresponse to treatment (19) .
Statistical Analysis. Categorical and continuous data are presented as percentage and as mean ± sd (or median and interquartile range), respectively. Categorical variables were compared using the chi-square (with Yates correction) or Fisher's exact tests. Quantitative continuous variables were compared using the unpaired t test or the Mann-Whitney test for normally and non-normally distributed variables, respectively.
Kaplan-Meier analysis was used to compare the effects of the use of corticosteroids (or lack thereof) on 28-day survival; the probability of survival between groups was analyzed using the log-rank test. Crude and adjusted survival between groups was analyzed using Cox regression with 28-day survival as the dependent variable. Stepwise backward Cox proportional hazard regression was used to determine factors associated with survival. The initial model consisted of all the independent variables that had a p value of <.200 in the bivariate analysis associated with outcome or between-group differences. Variables were removed one at a time if they did not contribute to the model assessed by the likelihood ratio test (p < .050). The hazard ratio and corresponding 95% confidence interval of each variable were computed. Proportionality among the event rates in the Cox models was assessed by the plot of the log (−log [survival function]) vs. time and by analyzing smoothed plots of Schoenfeld residuals. Linearity of continuous variables was assessed by analyzing the smoothed martingale residual plot. To investigate the lack of fit of our final model, we evaluated the deviance residuals. Single collinearity was evaluated using the Pearson correlation, and multicollinearity was examined by means of a correlation matrix of regression coefficients.
A propensity score for corticosteroid use was developed (12, 14, 31, 32) because the corticosteroid therapy was not randomly administered to these patients, resulting in a potential confounding factor and selection bias. The propensity score was determined, irrespective of the outcome, through a multivariate logistic regression to predict the influence of 33 predetermined variables on the use of corticosteroids. Variables were chosen for inclusion in the propensity score calculation according to the methods of Brookhart et al (33) and included variables associated with corticosteroid use and outcome (age, gender, chronic liver disease, chronic heart disease, chronic renal failure, chronic respiratory disease, neoplasia, diabetes mellitus, hospital admission and antibiotic use in the previous 90 days, chronic steroid use, days of admission before pneumonia diagnosis, APACHE II and SOFA at admission to the ICU, postoperative hypoxemic respiratory failure, decreased consciousness, hypercapnic respiratory failure, septic shock, nonsurgical abdominal disease, multiple trauma, acute coronary syndrome, cardiac arrest, other diagnosis at admission, VAP/NV-ICUAP, CPIS score on pneumonia diagnosis, number of lobes involved, shock at pneumonia diagnosis, ARDS criteria, pleural effusion on diagnosis, bacteremia, etiologic diagnosis, and treatment failure). The score was finally entered as a continuous variable into the Cox regression analysis to predict 28-day survival (12, 32, 34) . To evaluate possible overfitting and instability of selection variables in our final model, we performed an internal validation with a bootstrapping procedure with 1,000 replications.
To examine the relationship between the cumulative dosage of corticosteroid and the likelihood of mortality at 28 days, we constructed a generalized propensity score (35) . The score was created using a linear regression model, and was later included in the Cox regression analysis (36) . Sensitivity analyses were carried out to investigate the effects of factors potentially associated with patients outcome and corticosteroid use: illness severity and organ damage (APACHE-II and SOFA scores, respectively) (37), VAP instead of NV-ICUAP, bacteremia, etiologic diagnosis, nonresponse to treatment, ARDS, septic shock, chronic respiratory disorders, and long-term corticosteroid use. Also, the same overall analyses were performed on the subset of acutely exposed patients.
A two-sided p value ≤.05 was considered statistically significant. All statistical analyses were performed using SPSS 19.0 (SPSS Inc, Chicago, IL) and SigmaPlot 11.0 (Systat Software, San Jose, CA).
RESULTS
Patients Characteristics. We prospectively analyzed 316 consecutive patients ( Fig. 1) . One hundred twenty-five (40%) patients had received systemic corticosteroids at the moment of ICU-acquired pneumonia diagnosis. The indications for systemic corticosteroids therapy, the administered drugs, and the cumulative dose are shown in Table 1 . Importantly, there were no patients in the no treatment group who had received steroids in the previous 24 hrs or who were below our threshold (20 mg/day).
The characteristics of patients at admission to the ICU and on diagnosis of pneumonia are shown in Tables 2 and 3 . Patients in the systemic corticosteroids group were less frequently affected by chronic heart diseases and tended to have a higher simplified CPIS score. Although body temperature on diagnosis of pneumonia was lower in the corticosteroids group, the rates of fever and hypothermia were similar. The reasons for ICU admission were different between groups, with higher proportions of decreased consciousness and multiple trauma, and a lower proportion of postoperative respiratory failure among patients receiving systemic corticosteroids.
Outcomes. The prevalence of nonresponse to treatment, appropriateness of empiric treatment, other complications, and length of stay were similar between groups (Table 4) . However, patients receiving corticosteroid treatment had lower 28-day survival (Fig. 2) .
In addition to the corticosteroid therapy, lower 28-day survival was associated in the univariate analyses with age, APACHE-II score at admission, chronic liver disease, chronic heart disease, chronic respiratory disease, multiple trauma and cardiac arrest at admission to the ICU, SOFA score and septic shock at onset of pneumonia late-onset pneumonia, number of affect lobes, potentially drug resistant, nonfermenting Gram-negative bacilli and Pseudomonas aeruginosa pathogens, and nonresponse to treatment.
In the propensity-adjusted multivariate analysis, death remained significantly associated with corticosteroid therapy, age, chronic heart disease, chronic liver disease, chronic respiratory disease, multiple trauma, acute coronary syndrome, postoperative and decreased consciousness status and cardiac arrest at admission to the ICU, SOFA score at pneumonia onset, and nonresponse to treatment. Survival at 28 days adjusted for these variables remained significantly lower in patients receiving corticosteroids (p = .017, Table 5 ). All variables remained significant after a bootstrapping procedure with low bias (for corticosteroid treatment: p = .018, bias = 0.011). Among patients receiving corticosteroid treatment, there was no significant association between the cumulative dosage of the corticosteroids and the propensity-adjusted risk of death (Fig. 3) . Of the 103 patients that died, 84 (81%) died in the ICU, and there were no differences between groups (p = .88) with respect to the causes of death. Multiple organ failure (74/103) was the most common cause, followed by refractory hypoxemia (13/103).
The sensitivity analyses showed that previous systemic corticosteroids were associated with a higher risk of death at 28 days for patients with less severe clinical status, such as APACHE-II <20, SOFA <8, as well as in absence of the following features at onset of ICU-acquired pneumonia: ARDS criteria, septic shock, bacteremia, and etiologic diagnosis. Likewise, increased risk of death was found in patients undergoing corticosteroid therapy who developed NV-ICUAP instead of VAP and those without chronic respiratory disorders or without long-term corticosteroid use (Table 5 ).
Chronically exposed patients tended to show a poorer survival in an univariate analysis (hazard ratio 1.563, 95% confidence interval 0.940-2.599, p = .09) and similar secondary outcomes, except for shorter length of stay in the ICU (13 [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] vs. 17 [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] , p = .050) when compared to acutely exposed patients. We therefore performed another sensitivity analysis on the subset of patients without chronic exposure to corticosteroids. Of these 276 (87%) acutely exposed patients, differences between treated and no treated groups were similar to data for the entire cohort. After the same procedures, corticosteroid treatment remained associated with poor survival (propensity-adjusted hazard ratio 2.498, 95% confidence interval 1.037-6.018, p = .041).
Microbiologic Findings. Data are shown in Table 6 . An etiologic diagnosis was obtained in 204 (65%) patients, with a tendency towards a higher rate in patients receiving systemic corticosteroids (p = .10). Although we found a similar frequency of clinical late pneumonia, higher rate of microbiologic late-onset pneumonias was found in the corticosteroid group (74/100, 74% vs. 81/139, 58%, p = .020). Aspergillus species was more frequently found in patients with systemic corticosteroids (both in acutely and chronically exposed patients-four and two cases, respectively), with a trend toward a higher rate of nonfermenting Gram-negative bacilli (p = .084) and lower rate of methicillin-resistant Staphylococcus aureus (p = .052), compared with nontreated patients.
Of the 355 respiratory samples processed for culture on diagnosis of pneumonia, patients receiving corticosteroid treatment showed a greater frequency of high bacteria count (>10 5 colony-forming In respiratory samples with a positive culture from patients treated with corticosteroids, an increased risk for high bacterial growth was associated with the cumulative dosage per day of steroid therapy in a time-dependent analysis (Fig. 4A ). We were able to identify a threshold of 55 mg/day of steroid therapy for a clearly high relative risk of increased bacterial count (Fig. 4B) . Importantly, we were unable to find a positive association between poor outcomes and microbiologic definition or bacterial burden.
Inflammatory Response. The median serum levels of all inflammatory biomarkers were above the normal ranges in the overall population and no significant differences were found when comparing patients with and without etiologic diagnosis. Conversely, lower levels of C-reactive protein, procalcitonin, interleukin-6, and tumor necrosis factor-α were found in patients receiving systemic corticosteroid treatment (Table 7) .
DISCUSSION
The most important findings of our study are the following: 1) systemic corticosteroids were frequently administered prior to the development of ICU-acquired pneumonia; 2) patients receiving steroids had a higher bacterial lung burden; and 3) after a robust adjustment, corticosteroid use prior to the onset of pneumonia was associated with decreased 28-day survival.
Corticosteroids are widely indicated in critical care settings (9-12, 14, 32). The most common indications are exacerbation of chronic respiratory disease, critical illness-related corticosteroid insufficiency, reduction of exacerbated inflammatory and immune response, continuing chronic treatment and, more recently, preventing early-onset pneumonia in multiple trauma patients (16) . Although corticosteroids have proven to provide substantial benefits in specific diseases such as Pneumocystis jiroveci pneumonia (9) and severe acute exacerbation of chronic obstructive pulmonary disease (38) , their use remains the subject of debate in patients with ARDS (9, 32), septic shock (11, 39) , acute traumatic brain injury (10, 16) , and severe community-acquired pneumonia (9, 11) . Furthermore, there are no clear guidelines regarding dosages and duration of corticosteroid treatment, which may lead to unnecessary prolongation of treatment. In our study, 40% patients with ICU-acquired pneumonia had previously received steroids, thus confirming the frequent use of these drugs in critically ill patients.
To the best of our knowledge, this is the first study to specifically assess the use of corticosteroids in a large ICU population with nosocomial pneumonia. Thus, these findings are highly distinctive because, despite the frequent use of these drugs in the ICU, patients undergoing corticosteroid treatment are frequently excluded from clinical trials (6, 40) and observational studies (22) , or treatment with steroids may not be reported (41) . As a result, these patients are frequently included in the heterogeneous immunosuppressed population (42) . Our results are therefore highly relevant for clinical practice and future research, particularly due to the consistent debate regarding outcomes of patients with ICU-acquired pneumonia (6) .
Similar to the results of a previous report in a mixed ICU population (12) , patients who received steroids showed higher microbial growth in respiratory samples and a tendency toward a higher rate of microbial diagnosis compared to controls. This interesting finding may be because corticosteroids hindered the inflammatory response and therefore were able to attenuate the clinical presentation, thereby delaying the clinical suspicion of pneumonia. This delay explains the subsequent increase in CPIS score and microbial burden. An additional factor to be taken into account is that cumulative dosages showed a positive association with increased microbial growth in the lungs. This result was supported by the same time-risk to colonization/infection between groups. Indeed, treated and no treated patients remained similar periods -, Adjusted hazard ratio was not performed for the variables response to treatment and chronic respiratory disorder because they were included in the final model of multivariate analysis. For septic shock it was not calculated because there was a strong correlation between septic shock and Sequential Organ Failure Assessment (SOFA) score.
a Adjusted for variables (age, chronic heart disease, chronic liver disease, chronic respiratory disease, postoperative, decreased consciousness, acute coronary syndrome, multiple trauma and cardiac arrest at intensive care unit admission, SOFA score on diagnosis of pneumonia, nonresponse to treatment, and the propensity score);
b Acute Physiology and Chronic Health Evaluation-II and SOFA scores at intensive care unit admission; c adjusted hazard ratio for septic shock was not calculated because SOFA score replaced this variable in the multivariate analysis for factors associated with 28-day mortality. under three different conditions to bacterial growth: similar lengths of hospital stay before ICU admission, ICU stay, and days under mechanical ventilation. Altogether, these results suggest that the antiinflammatory effect may be associated with a more subacute initial presentation, which may result in delayed diagnosis and management, and a protracted course (43) (44) (45) .
A high rate of definitive etiologic diagnosis among patients with pulmonary infiltrates receiving corticosteroids has also been reported (21) . In line with previous reports, we found that patients show an increased prevalence of fungal pneumonia, with a tendency toward a higher rate of isolation of nonfermenting Gram-negative bacilli (mainly P. aeruginosa) when treated with corticosteroids (1, 12-14, 21, 46) . The latest American Thoracic Society/Infectious Diseases Society of America guidelines (1) recommend covering multidrug resistant microorganisms when immunosuppressive treatment is being administered. However, corticosteroids are not specifically mentioned. In the older ATS guidelines (46) , corticosteroid treatment was a risk factor for nonfermenting Gramnegative bacilli. In addition, the attending physician may be concerned about Aspergillus species infection in patients that have received steroids. Despite the limitation of low prevalence of fungal pneumonia (six patients) in our study, these infections were presented in both acutely and chronically exposed patients, and the mortality rate for these patients was high (50%). These findings should perhaps be taken into account for new nosocomial pneumonia guidelines.
The local and systemic inflammatory response is often increased in patients with ICU-acquired pneumonia (18, 21, 47, 48) and is associated with higher mortality (19, 48) . Although the anti-inflammatory effect and possible attenuation of a disproportionate host inflammatory response may partially explain the benefits associated with these drugs (9, 11, 16, 48) , one drawback may be the potential risk of acute ICU infections and an imbalance in the inflammatory response. In our study, the systemic inflammatory response was clearly attenuated in patients who received corticosteroid treatment. Our findings suggest that, in these particular settings, these drugs may present associated risks that overcome the benefits. As might be expected, four types of steroids were used in our observational design. This fact constitutes a limitation in our analysis of the inflammatory, glucocorticoid, and physiologic effects of these drugs in patients with ICU-acquired pneumonia, as the different drugs have different properties.
In our study, systemic corticosteroid use was associated with higher risk of death, particularly after adjusting for predefined variables associated with mortality and a propensity score for receiving corticosteroid therapy. This finding is in line with previous observational studies that found lower survival in mixed critically-ill patients (12) , sepsis (14, 17) , and influenza A H1N1 respiratory infection (32) . In addition, our results confirm that corticosteroids are potentially harmful in less severely ill patients and in those at low risk of death (9, 11, 14, 39, 49) . Interestingly, in the subset of acutely exposed patients, this association remained important. In more severe patients, such as those with SOFA ≥8 and ARDS criteria, corticosteroids were not associated with increased risk of mortality. We do not have a clear explanation for these findings, but similar results were reported in animal models (48) , and in humans with severe community-acquired pneumonia and acute respiratory failure (50) . The acute administration of steroids may have some beneficial effects in gas exchange and attenuation of systemic inflammatory response without changes in mortality. In contrast, in the less severe population, corticosteroids may decrease the inflammatory response to a critical point, at which the risk of infections is enhanced (21, 32) . This pattern suggests that steroid therapy is better able to control the inflammatory response when it is excessive, while increasing the risks in the subgroup with normal or decreased inflammatory response (39, 49) . Thus, in our study, we found that corticosteroid use impaired the host inflammatory response and probably led to a more severe infection or delayed clinical suspicion, both with high bacterial grow. The inflammatory response to injury is definitely complex, and worse outcomes were observed in both an exaggerated and hyporesponsive pattern. Patients who survive critical illness appear to respond with just right degree of inflammatory response, and the use of steroids alters this reaction (39) . Hence attending physicians must be aware that this dual (no change and increase) effect of steroids may occur and should exercise due caution when using these drugs.
Some limitations of our study should be taken into account. First, this study was conducted in a single center and therefore the extrapolation of the findings to other settings should be done with caution. Second, because of the noninterventional design, this study is not able to define clinical benefit or indications for steroid use. Conversely, we have achieved our purpose of describing the influence of previous steroid therapy in the natural history of ICU-acquired pneumonia-a frequent major cause of morbidity and mortality in the ICU. Third, it can be argued that some patients without etiologic diagnosis (counts below the threshold) may not actually have had pneumonia. However, our rate of etiologic diagnosis was similar to ancillary reports in this field. Furthermore, in our population, the simplified CPIS score and the serum levels of biomarkers were similar in patients with and without etiologic diagnosis. Fourth, we have no information regarding critical illness-related corticosteroid insufficiency, and it was not possible to run sensitivity analyses. Fifth, the propensity-score analysis does nothing to balance for unmeasured covariates, and some confounding factors may still be present. Sixth, we are unable to define whether poor outcomes of corticosteroid treatment are specific to ICU-acquired pneumonia or may be related to mechanical ventilation in general. This issue requires further research.
CONCLUSIONS
In critically-ill patients, systemic corticosteroids should be used very cautiously because this treatment is strongly associated with increased risk of death in patients with ICU-acquired pneumonia, particularly in the absence of established indications and in patients at low risk of death. Decreased inflammatory response may result in a more severe disease or in a delayed clinical suspicion of ICU-acquired pneumonia. Empirical antibiotic treatment should be appropriately aimed at nonfermenting Gram-negative bacilli in this population. .96 Tumor necrosis factor-α day 1, pg/mL 9 [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] 6 [4] [5] [6] [7] [8] [9] .003 Tumor necrosis factor-α day 3, pg/mL 9 [6] [7] [8] [9] [10] [11] [12] [13] [14] 6 [4] [5] [6] [7] [8] [9] [10] [11] .003
a At onset of pneumonia, C-reactive protein was assessed in 296 patients, and procalcitonin, midregional proadrenomedullin, and other cytokines in 190 patients. On the third day after pneumonia diagnosis, serum levels of C-reactive protein were evaluated in 278 patients, and the other biomarkers were evaluated in 158 patients.
